Drug Type Small molecule drug |
Synonyms R 1772, R-1772, R-7112 + [2] |
Target |
Mechanism MDM2 inhibitors(p53-binding protein Mdm-2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC38H48Cl2N4O4S |
InChIKeyQBGKPEROWUKSBK-QPPIDDCLSA-N |
CAS Registry939981-39-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Phase 1 | US | 01 Jul 2012 | |
Acute Myeloid Leukemia | Phase 1 | CA | 01 Jul 2012 | |
Acute Myeloid Leukemia | Phase 1 | FR | 01 Jul 2012 | |
Acute Myeloid Leukemia | Phase 1 | IT | 01 Jul 2012 | |
Acute Myeloid Leukemia | Phase 1 | GB | 01 Jul 2012 | |
Soft Tissue Sarcoma | Phase 1 | US | 01 May 2012 | |
Soft Tissue Sarcoma | Phase 1 | FR | 01 May 2012 | |
Lymphoma | Phase 1 | US | 01 Aug 2010 | |
Liposarcoma | Phase 1 | FR | 01 Jun 2010 | |
Acute Lymphoblastic Leukemia | Phase 1 | US | 01 May 2008 |
Phase 1 | 106 | vakoyugias(carzoezymf) = Adverse events included nausea/GI and exposure-related neutropenia/thrombocytopenia skprlzazgg (ouvxtqcpeo ) View more | - | 20 May 2012 |